AstraZeneca (ADR) (AZN)
Develops oncology-led medicines spanning rare diseases, cardiovascular care, metabolism, respiratory disease, and immunology.
Something off on this page? Send us feedback.
Develops prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology. Sold in more than 125 countries, the portfolio is oncology-led and shaped by clinical evidence, regulatory approval, patent exclusivity, supply execution, and reimbursement.
Develops and commercializes prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism and Respiratory & Immunology. The portfolio is sold in more than 125 countries, with oncology now the primary growth and research engine.
Science-led portfolio selection concentrates resources on drug candidates through staged development decisions. Antibody-drug conjugates, immuno-oncology, cell therapy, multispecific antibodies, rare-disease biologics, and AI-enabled discovery extend a base rebuilt after major patent expiries.
Performance depends on clinical evidence, regulatory approvals, manufacturing and supply execution, patent exclusivity, and pricing and reimbursement rules. Pending proceedings involving the China subsidiary add a current legal and compliance dependency, while the allegations remain unresolved.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 15, 2026 | Deutsche Bank | Upgrade | ||
| Sep 8, 2026 | RBC Capital | Initiate | Rating: — | |
| Aug 23, 2026 | CICC | Initiate | Rating: — | |
| Jul 13, 2026 | HSBC | Downgrade | ||
| Jul 9, 2026 | KeyBanc | Downgrade | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.96B · Total debt $32.20B · Total assets $115.70B · Shareholders' equity $50.24B
- Revenue
- $15.38B
- Operating income
- $3.16B
- Net income
- $2.51B
HistoryDividendAnnual yield
| Institutions | ≈ 105.83% | 820.47M ADS | |
|---|---|---|---|
| 1,521 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.00% | 19.3K ADS | |
| 1 holder · as of Sep 11, 2026 | |||
| Adds to | 105.83% | ||
775.27M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 105.83%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Investor ABInstitution | 6.65% | 51.59M ADS | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 5.85% | 45.39M ADS | as of Jun 30, 2026 |
Capital International InvestorsInstitution | 4.46% | 34.58M ADS | as of Jun 30, 2026 |
Norges BankInstitution | 4.37% | 33.86M ADS | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 3.88% | 30.08M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 8, 2026 | Mani Sharma | officer: See Remarks | +20 | $160.57 |
| May 20, 2026 | Mani Sharma | officer: See Remarks | −11,893 | $185.78 |
- Merck
Leads a rival immunotherapy franchise across major solid tumors
- Bristol-Myers Squibb
Contests multiple lung, liver, and gastrointestinal cancer markets
- GSK (ADR)
Competes in endometrial immunotherapy and ovarian PARP maintenance
- Novartis (ADR)
Competes in PNH complement therapy and severe-asthma biologics
- Pfizer
Overlaps in breast and bladder cancer therapeutics
- Eli Lilly
Overlaps in CLL/SLL treatment and type 2 diabetes
- Sanofi (ADR)
Biologic rival in eosinophilic asthma
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| AstraZeneca (ADR) | $166.74 | −0.81% | $260.70B | 25.2 | 15.7 | 4.2 | +6.4% |
| Merck | $148.10 | −0.94% | $369.24B | 119.6 | 17.2 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $62.03 | −0.95% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| GSK (ADR) | $50.26 | −1.61% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| Novartis (ADR) | $140.03 | −0.67% | $267.96B | 21.3 | 14.9 | 4.8 | +0.9% |
| Pfizer | $27.50 | −0.87% | $158.10B | 36.7 | 9.8 | 2.5 | +2.6% |
| Eli Lilly | $1,140.28 | −2.11% | $1.10T | 39.1 | 27.9 | 13.8 | +47.7% |
| Sanofi (ADR) | $42.03 | −1.11% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Median | 36.7 | 12.4 | 2.6 | +5.3% |